PatientsVille.com Logo

Migraine prophylaxis and Bengay

PatientsVille

Migraine Prophylaxis Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for migraine prophylaxis

migraine prophylaxis treatment research studies

Bengay clinical trials, surveys and public health registries


Find Drug Side Effect reports



Bengay Side Effects

Application Site Burn (40)
Application Site Erythema (26)
Pain (25)
Burns Second Degree (23)
Blister (20)
Application Site Vesicles (19)
Application Site Irritation (11)
Application Site Pain (11)
Scar (11)
Product Quality Issue (11)
Application Site Pruritus (10)
Skin Exfoliation (10)
Caustic Injury (8)
Chemical Injury (8)
Application Site Discolouration (8)
Eye Swelling (7)
Skin Discolouration (6)
Pruritus (5)
Rash Pruritic (5)
Feeling Abnormal (5)
Oedema Peripheral (4)
Burning Sensation (4)
Swelling Face (4)
Application Site Rash (4)
Application Site Reaction (4)
Off Label Use (3)
Gait Disturbance (3)
Vision Blurred (3)
Urticaria (3)
Scab (3)
Accidental Exposure (3)
Erythema (3)
Bacterial Infection (3)
Back Pain (3)
Application Site Infection (3)
Abdominal Pain (3)
Hypertension (3)
Thermal Burn (3)
Burns Third Degree (3)
Rash Erythematous (3)
Rash (3)
Dyspnoea (3)
Open Wound (3)
Discomfort (3)
Hypoaesthesia Oral (3)
Dermatitis (3)
Cerebrovascular Accident (3)
Impaired Work Ability (3)
Pyrexia (2)
Dysstasia (2)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Burning, Large red rash -looks like shingles. Needs to take OFF the market.

Can you get a rash from bengay cream if so how to treat it.

Feet irretation burns

Feet skin irretation reaction from bengay.skin burns on feet

Horrible burning sensation immediately after putting it on my lower back. It turned really red like a sunburn.

I did not use ben-gay i went into my grandother's home and could not breathe, severe coughing, feeling nausea, just horrible, had to leave

I got red rashes which developed into blisters on my hand where ever i applied bengay. Please suggest me a remedy.

I hated it! It burns like crazy! Don't try without have a real muscle ache!

I have used BenGay for many years now and since January and a car accident I have used it daily (allot) on my rotator cuff tear and back and knee. I started experiencing severe headaches and awful dizziness and stomach distress where I land

I left a bengay heating pad on for 8 hours as directed and then removed it after. Then about 5 minutes later my skin started itching and turning red. I broke out with pimples as well. Its been irritating for 3 days now and nothing is working! I've tr

My son was suffering from Head ache for the past one year. I have taken him to an ENT & he prescribed Sibelium 10 mg. & he was taking sibelium 3 months back for migraine and he was experiencing fatigue and drowsiness every day. Every t

<i>it was really painfull in my stomach after 5mins of taking ponstan,but i cant stop, to relieve pain for my terrible migraine!!! suggest please any medicine to replace PONSTAN,thanks!</i>

Is it effective for cases of migraine

After chewing nicorettes for a week or so I began to experience migraine aura, confusion, loss of cognitive ablities, nausea, jaw ache.

After receiving daily shots of Kenalog for 1 month for allergies and stopping, about a week later my blood pressure went from the usual 120/80 to an average 145/105 with migraine headaches. I had also gotten tiny bumps on my forehead. It lasted abou

Although low dose, novynette has caused constant migraine, gas, nausea, poor sleep, mood swings. Not happy, but skin seems improved. It's been one and a half weeks.

Aside from being on my 8th day of a migraine...I also have terrible aches in my legs and wozziness in my head at times. Almost like tunnel vision. Trouble sleeping, dreaming constantly. Shortness of breath and abnormally tired.

At first I just felt tired for about 5 hours, then horrible flu like symptoms. Pain, migraine headache, fever, muscle aches, general feeling of pain and discomfort and fever, worsening of colitis symptoms. It was a horrible experience. I had to deba

Been on symbicort for three weeks, experiencing headaches and today have migraine, also leg (calf) cramps. for last two days have been having what feels like bronchospasms. Interestingly symptoms have worsened since increasing dose frequency under Dr

Did panandeine can use for migraine??? can get it at pharmacy??

Migraine Prophylaxis Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting Manipulating Tobacco Constituents in Female Menthol Smokers
Condition: Nicotine Dependence
Interventions: Other: Reduced Nicotine;   Other: Reduced Nicotine Content-Menthol;   Other: Conventional Nicotine-Menthol;   Other: Conventional Nicotine
Outcome Measures: The goal of the cigarette conditions is to find the impact of varying nicotine and menthol concentrations on smoking rate and abstinence.;   Toxicant Exposure
2 Recruiting A Multicenter Efficacy Study of a Diclofenac+Menthol Gel in Subjects With Ankle Sprain
Condition: Ankle Sprain
Interventions: Drug: 1% diclofenac sodium plus 3% menthol;   Drug: 1% diclofenac sodium plus 0.09% menthol;   Drug: 3% menthol;   Drug: Placebo with 0.09% menthol gel
Outcome Measures: AUC (1-3 days);   Pain Intensity Difference (PID) on movement;   PID at rest;   Pain Relief Score (PRS);   Sum of Pain Intensity Difference (SPID);   Time of Onset of Pain Relief (TOPR);   Time of Onset of Meaningful Pain Relief (TOMR);   Time of Onset of Cooling Sensation (TOCS);   Total Pain Relief (TOTPAR);   Skin Temperature;   Ankle Swelling;   Time to complete Recovery;   Patient's Global Assessment in Response to Treatment (PGART);   Adverse events (AEs)
3 Recruiting The Effects of Menthol as Delivered by an Electronic Cigarette on the Desirability of Nicotine in Tobacco Users
Condition: Nicotine Dependence
Interventions: Drug: IV nicotine;   Drug: Tobacco Flavor;   Drug: Low dose Menthol;   Drug: High Dose Menthol
Outcome Measure: Peak Change on Items of the Drug Effects Questionnaire (DEQ)
4 Recruiting Reduced Exposure Study Using the Tobacco Heating System 2.2 (THS 2.2) Menthol for 91 Days in Confinement and Ambulatory
Condition: Smoking
Interventions: Other: THS 2.2 Menthol;   Other: SA;   Other: mCC
Outcome Measures: The evaluation of the total levels of monohydroxybutenyl mercapturic acid (MHBMA); 3-hydroxypropylmercapturic acid (3-HPMA); S-phenylmercapturic acid (S-PMA); total4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (total NNAL) in 24 hours urine.;   The evaluation of the total levels of carboxyhemoglobin (COHb) in blood.
5 Recruiting Effects and Safety of Menthol on Blood Pressure and Metabolic Parameters in Prehypertensive and Mild Hypertensive Patients
Conditions: Hypertension;   Prehypertension
Interventions: Drug: Menthol;   Drug: Placebo
Outcome Measure: The decrease in diastolic blood pressure after an 8-week oral menthol administration
6 Recruiting Reduced Exposure Study Using the Tobacco Heating System 2.2 (THS 2.2) Menthol for 90 Days in Confinement and Ambulatory
Condition: Smoking
Interventions: Other: THS 2.2 Menthol;   Other: SA;   Other: mCC
Outcome Measures: To demonstrate the levels of monohydroxybutenyl mercapturic acid (MHBMA); 3-hydroxypropylmercapturic acid (3-HPMA); S-phenylmercapturic acid (S-PMA) expressed as concentration adjusted to creatinine in 24-hour urine and carboxyhemoglobin (COHb) in blood.;   To demonstrate the levels of Total 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanol) (Total NNAL)
7 Recruiting STOPAIN in the Treatment of a Single Migraine Attack
Condition: Migraine
Intervention: Drug: STOPAIN topical gel
Outcome Measures: Efficacy of STOPAIN in the Acute Treatment of Migraine;   evaluate the tolerability, safety, and sustained pain freedom of STOPAIN
8 Not yet recruiting Acute Effect of Topical Menthol on Neck Pain
Condition: Musculoskeletal Disorders
Interventions: Other: Biofreeze;   Other: Placebo
Outcome Measures: Neck pain intensity (scale 0-10);   Pressure pain threshold (PPT)
9 Not yet recruiting EverFlex™ Self-expanding Peripheral Stent With Entrust™ Delivery System Clinical Study
Condition: Peripheral Arterial Diseases
Intervention: Device: EverFlex™ Stent with Entrust™ Delivery System
Outcome Measures: Absence of stent elongation;   Successful stent deployment
10 Recruiting Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Conditions: Breast Cancer;   Colon Cancer
Interventions: Other: topical menthol;   Other: placebo cream
Outcome Measures: neuropathic pain;   functional tests
11 Recruiting Effectiveness of Biofreeze® on Shoulder Pain and In-office Exercise Performance
Condition: Shoulder Pain
Intervention: Drug: Biofreeze
Outcome Measures: Change from Baseline of American Shoulder and Elbow Surgeons (ASES) Questionnaire at 2 weeks;   Change from baseline of Numeric Pain Rating Scale (NPRS) at 2 weeks;   Change from baseline of American Shoulder and Elbow Surgeons (ASES) Questionnaire at 4 weeks;   Change from baseline of Numeric Pain Rating Scale at 4 weeks
12 Recruiting EverFlex Post Approval Study
Conditions: Peripheral Arterial Disease;   Lower Extremity Arterial Disease
Intervention: Device: EverFlex™ Self-Expanding Peripheral Stent System
Outcome Measure: Primary Outcome - Composite endpoint
13 Unknown  Osteoarthritis in Older Adults: Recovery of Mobility and Pain With a Topical Analgesic
Condition: Knee Osteoarthritis
Interventions: Drug: Biofreeze;   Other: Placebo
Outcome Measures: WOMAC score;   Quality of life measured using SF 36
14 Recruiting Self-operated Endo-vaginal Telemonitoring (SOET), an Economic and Patient-empowered Method for Ovarian Stimulation for In-vitro Fertilization (IVF)
Condition: IVF Treatment
Intervention: Device: Perform Echo at home.
Outcome Measure: Higher efficacy by taking an echo at home.
15 Recruiting Effects of Electronic Cigarettes on Nicotine Concentrations
Condition: Health Behavior
Interventions: Other: Nicotine with Tobacco Flavor;   Other: Nicotine with Tobacco and Menthol Flavor
Outcome Measures: Effects E-cig use on venous nicotine concentrations before and 5, 10, 15,20 and 30 minutes after use;   Effects of E-cig use on measures of pulmonary resistance before and 5 minutes after use
16 Recruiting Does Ultrasound Guidance Improve Time to Perform a Spinal or Number of Attempts in Obese Patients?
Condition: Spinal Anesthesia Administration.
Interventions: Procedure: Ultrasound guidance;   Procedure: Palpation of Tuffier's line;   Procedure: Spinal anesthetic
Outcome Measures: Total time to perform the spinal;   Time from administration of the local anesthetic needle until free flow CSF;   Number of needle redirections;   Number of attempts to complete the spinal;   Number of failed blocks
17 Unknown  Comparative Efficacy of the Suppository Versus Guaiacol Suppository Versus Guaifenesin Syrup in Pediatric Patients With Cough Due the Infectious Origin
Condition: Cough
Interventions: Drug: Guaiacol, eucalyptol, menthol and camphor suppository;   Drug: guaiacol suppository;   Drug: Guaifenesin syrup
Outcome Measures: Improvement of cough of infectious origin.;   Analysis of parameters for the improvement of infectious cough.
18 Recruiting A Test of the Comparison Between Trans-rectal and Trans-perineal Biopsy of Prostate
Condition: Complication
Interventions: Procedure: trans-rectal to perform the prostate biopsy;   Procedure: trans-perineal to perform the prostate biopsy
Outcome Measures: the rate of positive detections;   the incidence rate of each complication
19 Unknown  PERfusion CT in the FOXFIRE Trial to Study Blood Flow to Liver Metastases
Condition: Metastatic Colorectal Cancer
Intervention: Other: Perfusion CT scan
Outcome Measures: Recruitment rate to this voluntary study and acquisition of sufficient data for perfusion analysis;   Correlation between the tumour perfusion pattern on perfusion CT studies at baseline and shortly after the start of therapy and morphological response by RECIST criteria on CT scan 3 months post therapy in both arms of the FOXFIRE trial.
20 Recruiting St.Jude Medical Cardiac Lead Assessment Study
Condition: Prevalence of Externalized Conductors and Other Visual Lead Anomalies in Certain Family of High Voltage and CRT Leads
Intervention:
Outcome Measures: The prevalence of electrical dysfunction in the Riata, Riata ST, QuickSite/QuickFlex (1056T, 1058T, 1156T, 1158T) and Durata leads.;   The prevalence of externalized conductors in the Riata, Riata ST, QuickSite/QuickFlex (1056T, 1058T, 1156T, 1158T) and Durata leads.;   The prevalence of other visual lead anomalies by each subcategory (fracture, kink, subclavian crush, other irregularities) in the Riata, Riata ST, QuickSite/QuickFlex (1056T, 1058T, 1156T, 1158T) and Durata leads.;   The annual hazard rate of lead electrical dysfunction (from enrollment) conditional on implant year in the Riata, Riata ST, QuickSite/QuickFlex (1056T, 1058T, 1156T, 1158T) and Durata leads.;   The annual hazard rate of new cases of externalized conductors (from enrollment), by year of initial implant in the Riata, Riata ST, QuickSite/QuickFlex (1056T, 1058T, 1156T, 1158T) and Durata leads.;   The annual hazard rate of new cases of other visual lead anomalies by each subcategory (from enrollment), by year of initial implant in the Riata, Riata ST, QuickSite/QuickFlex (1056T, 1058T, 1156T, 1158T) and Durata leads;   Prevalence of "other insulation anomalies" in "returned leads" by year of initial implant in the Riata, Riata ST, QuickSite/QuickFlex (1056T, 1058T, 1156T, 1158T) and Durata leads.;   Time from enrollment to externalized conductors by year of initial implant;   Time from enrollment to other visual lead anomalies (evidenced by imaging) by year of initial implant and each subcategory.;   Time from enrollment to electrical dysfunction, by year of implant;   Time from externalized conductors to electrical dysfunction, by year of initial implant.;   Time from other visual lead anomalies by each lead subcategory to electrical dysfunction, by year of initial implant.;   Adverse Event rate through 30 days post-intervention for lead (e.g. extraction, abandonment, revision, other).;   Time from externalized conductors to clinical intervention;   Time from other visual lead anomalies by each subcategory to clinical intervention.;   Comparison of patients with lead compromise as evidenced by imaging (includes externalized conductors and other visual lead anomalies by each subcategory) to those without lead compromise.;   Comparison of patients with electrical dysfunction to those without electrical dysfunction.